Cedar Grove Capital Q3 2026 Portfolio UpdateSeeking Alpha · Oct 7, 2026
Abivax: Priced Right Ahead Of 2 Make-Or-Break CatalystsSeeking Alpha · Sep 23, 2026
These Analysts Slash Their Forecasts On Abivax Following H1 ResultsBenzinga · Sep 22, 2026
Abivax Presents Business Updates and First Half 2026 Financial ResultsGlobeNewsWire · Sep 21, 2026
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by BrokeragesDefense World · Sep 21, 2026
Accenture, Abivax and 3 Stocks to Watch Heading Into MondayBenzinga · Sep 21, 2026Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 21, 2026 | -$0.98 | -$1.71 | Miss |
| May 22, 2026 | -$1.07 | -$0.71 | Beat |
| Mar 23, 2026 | -$1.70 | -$1.19 | Beat |
| Dec 15, 2025 | -$0.79 | -$2.47 | Miss |
| Sep 8, 2025 | -$0.90 | -$0.86 | Beat |
| Jun 2, 2025 | -$0.76 | -$0.97 | Miss |